NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Technology News / Pfizer's COVID-19 vaccine shows promise in human trials: Details here
    Next Article
    Pfizer's COVID-19 vaccine shows promise in human trials: Details here

    Pfizer's COVID-19 vaccine shows promise in human trials: Details here

    By Shubham Sharma
    Aug 12, 2020
    10:35 pm

    What's the story

    The COVID-19 candidate vaccine jointly developed by American pharma giant Pfizer and German biotech company BioNTech has shown promise in early human trials.

    According to the interim data of the study published in journal Nature, the shot was able to generate a 'robust' immune response in all study volunteers, without any serious side effects.

    Here is all you need to know about it.

    Trial

    Phase-1/2 trial with 45 volunteers

    In the randomized, observer-blinded Phase-1/2 study, 45 healthy individuals, aged between 18 and 55 years, were enrolled as part of the trial.

    Out of the group, 24 were given two 10 µg or 30 µg doses of Pfizer vaccine - dubbed BNT162b1 - in a gap of 21 days, 12 were given a single 100 µg dose, and 9 received a placebo.

    Response

    All doses generated antibody protection

    After being vaccinated, the subjects were monitored for weeks, which allowed the team to establish the effectiveness of the shot.

    They found that all three doses of BNT162b1 generated neutralizing antibodies against COVID-19 by the 21st day.

    Importantly, their levels were found to be 1.9 to 4.6 times higher than those typically witnessed in patients recovering from the deadly disease.

    Stats

    Immune response increased with dose level

    The immune response increased with the level of the dose administered and grew substantially seven days after the second 10 µg or 30 µg dose was given.

    Notably, the immune response generated by 30 µg dose was stronger than that of the 10 µg shot, but there were no major differences between 30 μg and 100 μg group after a single dose.

    Safety

    No serious side effects recorded

    Along with being effective, the vaccine was also proven to be generally safe in the early trial.

    Only mild-to-moderate dose-dependent side effects were witnessed within seven days of vaccination, which included low-grade fever, particularly after the second dose, as well as pain at the injection site, fatigue, headache, fever and sleep disturbance.

    No serious health issue was reported in the study.

    Work

    Now, the team is proceeding with late-stage trials

    Now, Pfizer and BioNTech are moving through the Phase-2/3 trials with their candidate vaccines (BNT162b1 and its modified sibling BNT162b2), with the ultimate goal of getting emergency use approvals in the US by October 2020.

    If cleared, the companies aim to supply globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Pfizer
    Vaccine
    United States of America
    COVID-19

    Latest

    'Russia, Ukraine will immediately start ceasefire negotiations': Trump Donald Trump
    Decoding Premier League teams in race for Europe next season Premier League
    'Sirens,' 'Nine Perfect Strangers': Your OTT watchlist this week Amazon Prime Video
    'Fear Street: Prom Queen': Cast, plot, release details OTT releases

    Pfizer

    As Pfizer's Viagra patent ends, Indian firms prepare for dominance United States of America
    As coronavirus pandemic surges, some vaccine makers expect to profit Vaccine

    Vaccine

    Thane: Maulvis roped in to spread awareness about measles-rubella vaccine Maharashtra
    Nagaland: Measles Rubella vaccination campaign covers 98% of children Nagaland
    China disciplines 80 officials linked to major 2018 vaccine scandal China
    Boy, who got vaccinated against parents' wishes, to address Senate New Jersey

    United States of America

    No surprises here! Emmys will go virtual, courtesy coronavirus pandemic Emmy Awards
    NASA launches rover to find 'ancient Martian life' Space News
    The Lincoln Project: The conservative group pushing for Trump's ouster Donald Trump
    Trump suggests delaying 2020 US Presidential elections over mail-in voting Donald Trump

    COVID-19

    Coronavirus: India's tally reaches 15.8L with over 52,000 new cases India
    Haris Rauf to join Pakistan squad after negative COVID-19 tests Mohammad Amir
    Coronavirus: SC orders Centre to ensure timely salaries for healthcare-workers Supreme Court Of India
    Chinese hackers targeted COVID-19 vaccine maker Moderna: Report Reuters
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025